Advanced search
Publication Cover
Patient Preference and Adherence Volume 17, 2023 - Issue
Submit an article Journal homepage
268
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Medication Use Issues and Challenges of Mental Illness Exacerbation in Patients with Schizophrenia: A Qualitative Study in Thailand

Ponglapat Klinpiboon1 Department of Pharmacy, Nakhon Ratchasima Rajanagarindra Psychiatric Hospital, Nakhon Ratchasima, Thailand;2 Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, ThailandORCID Iconhttps://orcid.org/0009-0006-7688-6516
ORCID Icon &
Kornkaew Chanthapasa2 Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, ThailandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4773-375X
ORCID Icon
Pages 2927-2937 | Received 05 Sep 2023, Accepted 07 Nov 2023, Published online: 13 Nov 2023

References

  • Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693. doi:10.1001/jamapsychiatry.2017.1322
  • Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9(1):17. doi:10.1186/s13643-020-1274-3
  • Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218. doi:10.1177/2045125312474019
  • Dilokthornsakul P, Thoopputra T, Patanaprateep O, Kongsakon R, Chaiyakunapruk N. Effects of medication adherence on hospitalizations and healthcare costs in patients with schizophrenia in Thailand. SAGE Open Med. 2016;4:2050312116637026. doi:10.1177/2050312116637026
  • Javadi M, Zarea K. Understanding thematic analysis and its pitfall. Demo. 2016;1(1):33–39.
  • Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis: striving to meet the trustworthiness criteria. Int J Qual Methods. 2017;16(1):160940691773384. doi:10.1177/1609406917733847
  • Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the health belief model. Health Educ Q. 1988;15(2):175–183. doi:10.1177/109019818801500203
  • Sheffield JM, Karcher NR, Barch DM. Cognitive deficits in psychotic disorders: a lifespan perspective. Neuropsychol Rev. 2018;28(4):509–533. doi:10.1007/s11065-018-9388-2
  • Porcelli S, Bianchini O, De Girolamo G, Aguglia E, Crea L, Serretti A. Clinical factors related to schizophrenia relapse. Int J Psychiatry Clin Pract. 2016;20(2):54–69. doi:10.3109/13651501.2016.1149195
  • Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234–258. doi:10.1016/j.drugalcdep.2018.07.011
  • Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophr Res. 2018;194:78–85. doi:10.1016/j.schres.2017.04.016
  • Carey CE, Agrawal A, Bucholz KK, et al. Associations between polygenic risk for psychiatric disorders and substance involvement. Front Genet. 2016;7:149. doi:10.3389/fgene.2016.00149
  • Chiappini S, Mosca A, Miuli A, et al. Misuse of anticholinergic medications: a systematic review. Biomedicines. 2022;10(2):355. doi:10.3390/biomedicines10020355
  • de la Iglesia-Larrad JI, Barral C, Casado-Espada NM, et al. Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: a review of the literature. Psychiatry Res. 2020;284:112660. doi:10.1016/j.psychres.2019.112660
  • Mahal P, Nishanth KN, Mahapatra A, Sarkar S, Balhara YPS. Trihexyphenidyl misuse in delusional disorder. J Neurosci Rural Pract. 2018;9(3):428–430. doi:10.4103/jnrp.jnrp_569_17
  • Kazadi NJB, Moosa MYH, Jeenah FY. Factors associated with relapse in schizophrenia. South Afr J Psychiatry. 2008;14(2):7. doi:10.4102/sajpsychiatry.v14i2.158
  • Moges S, Belete T, Mekonen T, Menberu M. Lifetime relapse and its associated factors among people with schizophrenia spectrum disorders who are on follow up at comprehensive specialized hospitals in Amhara region, Ethiopia: a cross-sectional study. Int J Ment Health Syst. 2021;15:42. doi:10.1186/s13033-021-00464-0
  • Olivares JM, Sermon J, Hemels M, Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12:32. doi:10.1186/1744-859X-12-32
  • Perreau-Lenz S, Spanagel R. Clock genes × stress × reward interactions in alcohol and substance use disorders. Alcohol Fayettev N. 2015;49(4):351–357. doi:10.1016/j.alcohol.2015.04.003
  • Sahani V, Hurd YL, Bachi K. Neural underpinnings of social stress in substance use disorders. Curr Top Behav Neurosci. 2022;54:483–515.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.